These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26228073)

  • 1. Protective Role of Sodium-Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes.
    Yamagishi S; Matsui T
    Rejuvenation Res; 2016 Apr; 19(2):107-14. PubMed ID: 26228073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
    Maeda S; Matsui T; Takeuchi M; Yamagishi S
    Diabetes Metab Res Rev; 2013 Jul; 29(5):406-12. PubMed ID: 23508966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
    Ishibashi Y; Matsui T; Yamagishi S
    Horm Metab Res; 2016 Mar; 48(3):191-5. PubMed ID: 26158396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
    Cherney DZ; Perkins BA
    Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
    Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
    Bertinat R; Nualart F; Yáñez AJ
    J Cell Physiol; 2016 Aug; 231(8):1635-7. PubMed ID: 26661279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus.
    Ahmadieh H; Azar S
    Diabetes Technol Ther; 2017 Sep; 19(9):507-512. PubMed ID: 28749169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
    Deshmukh AB; Patel MC; Mishra B
    Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.
    Gill A; Gray SP; Jandeleit-Dahm KA; Watson AMD
    Curr Diabetes Rev; 2019; 15(5):349-356. PubMed ID: 29663893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent.
    Nomura S
    Curr Top Med Chem; 2010; 10(4):411-8. PubMed ID: 20180760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.